


# Biognosys Reaches Technology Breakthrough for Deep Tissue Profiling with the Bruker timsTOF HT Platform

New R&D workflow achieved a total depth of over 14,600 proteins across 22 different human tissues

**June 2, 2023. ZURICH, Switzerland and CAMBRIDGE, Mass.** Biognosys, a leading inventor and developer of mass spectrometry-based proteomics technology and solutions, announced today that their R&D team for the first time achieved a total depth of over 14,600 proteins across 22 different human tissues on the Bruker timsTOF HT platform. Biognosys is developing this new timsTOF workflow to continue pushing the boundaries of robust, fast, and deep tissue profiling.

In the R&D study, the Bruker timsTOF HT mass spectrometer was deployed with a pace of 1h injection to injection per proteome. The study benchmarked the platform using 22 different human tissues and achieved a total depth of over 14,600 proteins, with most proteins profiled in the testis and tonsil tissue samples. The results reveal a clear distinction between three cancerous tissues compared to the healthy tissues. Further, the human brain stands out as the most distinct from other tissues.

## Biognosys Deep Tissue Profiling R&D Workflow on the Bruker timsTOF HT Platform



The study demonstrates the exceptional performance of the timsTOF platform for deep tissue profiling to provide insights into disease and drug-relevant proteins, including those in the low-abundant range.

“Deep tissue profiling with the Bruker timsTOF platform can give insights into a large fraction of disease and drug-relevant proteins like kinases, transcription factors, histone deacetylases, and E3 ubiquitin ligases,” **commented Roland Bruderer, Ph.D., Head of R&D LC-MS and Workflows at Biognosys.** “Many of the quantified proteins are in the lower concentration ranges with a low abundance rank and could only be detected thanks to the high sensitivity of the workflow.”

The company is committed to making this enhanced performance available to customers via its TrueDiscovery™ research services platform.

## About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit [biognosys.com](http://biognosys.com).

## Media Contact

### Yves Serroen

Head of Marketing and Communications

Phone +41 (0) 44 244 50 07

[yves.serroen@biognosys.com](mailto:yves.serroen@biognosys.com)